{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:57:35Z","timestamp":1781647055846,"version":"3.54.5"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Anesthesiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Backgroud<\/jats:title>\n                    <jats:p>High-dose catecholamine use in distributive shock is associated with high mortality. Angiotensin II (ATII) has demonstrated benefits in distributive shock patients, yet limited and inconsistent clinical data precludes its publication in treatment guidelines. This overview of reviews aims to critically assess and summarize systematic reviews on ATII benefits in distributive shock, identify knowledge gaps, and provide recommendations for future research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>A systematic literature search for systematic reviews on the topic from 2020 was conducted, including PubMed, Embase, CINAHL, Epistemonikos, Scopus, PROSPERO, and Cochrane, and gray literature. Reviews were assessed by the Assessment of Multiple Systematic Reviews 2 (AMSTAR 2) checklist. Certainty of evidence was calculated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) tool. Both qualitative and quantitative data were summarized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The literature search yielded 239 results, resulting in 6 systematic reviews being included. The methodological quality was mostly low. ATII administration was associated with a decrease in background vasopressor requirements. Occurrence of serious adverse reactions were not found to be statistically significant. Mortality benefits was found in certain patient sub-groups but cannot be generalized. A consistent finding was that ATII improved MAP\u2009&gt;\u200910\u00a0mmHg from baseline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ATII appears to be a safe and effective vasopressor in distributive shock management. The physiological and logistical benefits should be considered early in distributive shock management. This overview of reviews has identified certain gaps in the definition of catecholamine-resistant shock, ATII initiation thresholds, biomarker guided treatment, and occurrence of hemodynamic relapse which may guide future aspiring clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12871-026-03797-w","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T05:35:19Z","timestamp":1775453719000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["An overview of reviews of Angiotensin II in distributive shock"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9118-3760","authenticated-orcid":false,"given":"Mathieu","family":"Desfosses","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"R\u00f8islien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"key":"3797_CR1","doi-asserted-by":"publisher","first-page":"155004","DOI":"10.1016\/j.jcrc.2024.155004","volume":"86","author":"HA Thompson","year":"2025","unstructured":"Thompson HA, Brinkman HM, Kashani KB, Cole KC, Wittwer ED, Wieruszewski PM. Early high-dose vasopressors in refractory septic shock: A cohort study. J Crit Care. 2025;86:155004. https:\/\/doi.org\/10.1016\/j.jcrc.2024.155004. Cited 2024 Dec 18.","journal-title":"J Crit Care"},{"issue":"1","key":"3797_CR2","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s13054-018-2102-1","volume":"22","author":"S Lambden","year":"2018","unstructured":"Lambden S, Creagh-Brown BC, Hunt J, Summers C, Forni LG. Definitions and pathophysiology of vasoplegic shock. Crit Care. 2018;22(1):174. https:\/\/doi.org\/10.1186\/s13054-018-2102-1. Cited 2023 June 12.","journal-title":"Crit Care"},{"key":"3797_CR3","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1164\/rccm.201911-2172OC","volume":"202","author":"R Bellomo","year":"2020","unstructured":"Bellomo R, Forni LG, Busse LW, McCurdy MT, Ham KR, Boldt DW, et al. Renin and Survival in Patients Given Angiotensin II for Catecholamine-Resistant Vasodilatory Shock. A Clinical Trial. Am J Respir Crit Care Med. 2020;202:1253\u201361. https:\/\/doi.org\/10.1164\/rccm.201911-2172OC. Cited 2024 Jan 24.","journal-title":"Am J Respir Crit Care Med"},{"key":"3797_CR4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1056\/NEJMoa1704154","volume":"377","author":"A Khanna","year":"2017","unstructured":"Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, et al. Angiotensin II for the treatment of vasodilatory shock. N Engl J Med. 2017;377:419\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1704154. Cited 2026 Feb 23.","journal-title":"N Engl J Med"},{"key":"3797_CR5","doi-asserted-by":"publisher","unstructured":"Bellomo R, Zarbock A, Landoni G. Angiotensin II. Intensive Care Med. 2024;s00134-023-07290-7. https:\/\/doi.org\/10.1007\/s00134-023-07290-7. Cited 2024 Jan 23.","DOI":"10.1007\/s00134-023-07290-7"},{"key":"3797_CR6","doi-asserted-by":"publisher","first-page":"e070849","DOI":"10.1136\/bmj-2022-070849","volume":"378","author":"M Gates","year":"2022","unstructured":"Gates M, Gates A, Pieper D, Fernandes RM, Tricco AC, Moher D, et al. Reporting guideline for overviews of reviews of healthcare interventions: development of the PRIOR statement. BMJ. 2022;378:e070849. https:\/\/doi.org\/10.1136\/bmj-2022-070849. Cited 2024 Nov 4.","journal-title":"BMJ"},{"key":"3797_CR7","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"O Mourad","year":"2016","unstructured":"Mourad O, Hossam H, Zbys F, Ahmed E. Rayyan \u2014 a web and mobile app for systematic reviews. Syst Rev. 2016;5:210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4.","journal-title":"Syst Rev"},{"key":"3797_CR8","unstructured":"Microsoft Corporation. Microsoft Excel. 2018. Available from: https:\/\/office.microsoft.com\/excel."},{"key":"3797_CR9","unstructured":"Bracchiglione J, Meza N, Bangdiwala E, Urrutia G. GROOVE - Graphical Representation of Overlap for OVErviews. GROOVE - Graphical Representation of Overlap for OVErviews.\u00a0https:\/\/osf.io\/u2ms4\/. Accessed 25 Jan 2025. Cited 2025 Jan 25."},{"key":"3797_CR10","doi-asserted-by":"crossref","unstructured":"Shea B, Reeves B, Wells G, Thuku M, Hamel C. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. 2017. https:\/\/amstar.ca\/Amstar_Checklist.php. Accessed 3 Nov 2024. Cited 2024 Nov 3.","DOI":"10.1136\/bmj.j4008"},{"key":"3797_CR11","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919. Cited 2024 Nov 3.","journal-title":"BMJ"},{"key":"3797_CR12","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. British Medical Journal Publishing Group; 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898. Cited 2024 Nov 3.","DOI":"10.1136\/bmj.l4898"},{"issue":"5","key":"3797_CR13","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/jrsm.1658","volume":"14","author":"M Kirvalidze","year":"2023","unstructured":"Kirvalidze M, Abbadi A, Dahlberg L, Sacco LB, Calder\u00f3n-Larra\u00f1aga A, Morin L. Estimating pairwise overlap in umbrella reviews: considerations for using the corrected covered area (CCA) index methodology. Res Synth Methods. 2023;14(5):764\u20137. https:\/\/doi.org\/10.1002\/jrsm.1658. Cited 2025 May 16.","journal-title":"Res Synth Methods"},{"key":"3797_CR14","unstructured":"GRADEproGDT [Computer program]. Version accessed 6 August 2023. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at https:\/\/www.gradepro.org."},{"issue":"1","key":"3797_CR15","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","volume":"10","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10(1):89. https:\/\/doi.org\/10.1186\/s13643-021-01626-4. Cited 2024 Apr 14.","journal-title":"Syst Rev"},{"key":"3797_CR16","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s10557-020-07098-3","volume":"36","author":"O Papazisi","year":"2022","unstructured":"Papazisi O, Palmen M, Danser AHJ. The use of angiotensin II for the treatment of post-cardiopulmonary bypass vasoplegia. Cardiovasc Drugs Ther. 2022;36:739\u201348. https:\/\/doi.org\/10.1007\/s10557-020-07098-3. Cited 2023 Oct 28.","journal-title":"Cardiovasc Drugs Ther"},{"key":"3797_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/OAEM.S391167","volume":"15","author":"BP Semedi","year":"2023","unstructured":"Semedi BP, Rehatta NM, Soetjipto S, Nugraha J, Mahyuddin MH, Arnindita JN, et al. How Effective is Angiotensin II in Decreasing Mortality of Vasodilatory Shock? A Systematic Review. OAEM. 2023;15:1\u201311. https:\/\/doi.org\/10.2147\/OAEM.S391167. Cited 2023 June 3.","journal-title":"OAEM"},{"key":"3797_CR18","doi-asserted-by":"publisher","unstructured":"Xourgia E, Exadaktylos AK, Chalkias A, Ziaka M. Angiotensin II in the treatment of distributive shock: a systematic-review and meta-analysis. Shock. 2024. https:\/\/doi.org\/10.1097\/SHK.0000000000002384. Cited 2024 Sept 13.","DOI":"10.1097\/SHK.0000000000002384"},{"key":"3797_CR19","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.3390\/life14091085","volume":"14","author":"A Alamami","year":"2024","unstructured":"Alamami A, Rahhal A, Alqudah B, Shebani A, Alammora A, Mohammad H, et al. Clinical outcomes of angiotensin II therapy in vasoplegic shock: a systematic review and meta-analysis. Life. 2024;14:1085. https:\/\/doi.org\/10.3390\/life14091085. Cited 2024 Sept 2.","journal-title":"Life"},{"key":"3797_CR20","doi-asserted-by":"publisher","unstructured":"Caragata R, Johnston SA, Chan JW, Starkey G, Bellomo R. Angiotensin-II and thromboembolic events: a systematic review. Crit Care Med. 2024. https:\/\/doi.org\/10.1097\/CCM.0000000000006433. Cited 2024 Oct 18.","DOI":"10.1097\/CCM.0000000000006433"},{"key":"3797_CR21","doi-asserted-by":"publisher","unstructured":"Caragata R, Johnston SA, Chan JW, Starkey G, Bellomo R. Angiotensin-II and Thromboembolic Events: A Systematic Review. Crit Care Med. 2024. https:\/\/doi.org\/10.1097\/CCM.0000000000006433. Cited 2024 Oct 18.","DOI":"10.1097\/CCM.0000000000006433"},{"issue":"4","key":"3797_CR22","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1177\/0885066618818460","volume":"35","author":"R Rodriguez","year":"2020","unstructured":"Rodriguez R, Cucci M, Kane S, Fernandez E, Benken S. Novel vasopressors in the treatment of vasodilatory shock: a systematic review of angiotensin II, selepressin, and terlipressin. J Intensive Care Med. 2020;35(4):327\u201337. https:\/\/doi.org\/10.1177\/0885066618818460.","journal-title":"J Intensive Care Med"},{"key":"3797_CR23","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1177\/0885066620972943","volume":"37","author":"SE Smith","year":"2022","unstructured":"Smith SE, Newsome AS, Guo Y, Hecht J, McCurdy MT, Mazzeffi MA, et al. A multicenter observational cohort study of angiotensin II in shock. J Intensive Care Med. 2022;37:75\u201382. https:\/\/doi.org\/10.1177\/0885066620972943.","journal-title":"J Intensive Care Med"},{"key":"3797_CR24","doi-asserted-by":"publisher","first-page":"e0623","DOI":"10.1097\/CCE.0000000000000623","volume":"4","author":"M Quan","year":"2022","unstructured":"Quan M, Cho N, Bushell T, Mak J, Nguyen N, Litwak J, et al. Effectiveness of Angiotensin II for Catecholamine Refractory Septic or Distributive Shock on Mortality: A Propensity Score Weighted Analysis of Real-World Experience in the Medical ICU. Crit Care Explor. 2022;4:e0623. https:\/\/doi.org\/10.1097\/CCE.0000000000000623. Cited 2023 June 8.","journal-title":"Crit Care Explor"},{"issue":"2","key":"3797_CR25","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.chest.2020.08.2074","volume":"159","author":"PM Wieruszewski","year":"2021","unstructured":"Wieruszewski PM, Wittwer ED, Kashani KB, Brown DR, Butler SO, Clark AM, et al. Angiotensin II infusion for shock. Chest. 2021;159(2):596\u2013605. https:\/\/doi.org\/10.1016\/j.chest.2020.08.2074. Cited 2023 June 7.","journal-title":"Chest"},{"issue":"1","key":"3797_CR26","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/SHK.0000000000002481","volume":"63","author":"A Chaba","year":"2025","unstructured":"Chaba A, Zarbock A, Forni LG, H\u00e4stbacka J, Korneva E, Landoni G, et al. Angiotensin II for Catecholamine-Resistant Vasodilatory Shock In Patients With Acute Kidney Injury: A Post Hoc Analysis of The ATHOS-3 Trial. Shock. 2025;63(1):88. https:\/\/doi.org\/10.1097\/SHK.0000000000002481. Cited 2026 Mar 10.","journal-title":"Shock"},{"key":"3797_CR27","doi-asserted-by":"publisher","first-page":"e2211370119","DOI":"10.1073\/pnas.2211370119","volume":"119","author":"DE Leisman","year":"2022","unstructured":"Leisman DE, Privratsky JR, Lehman JR, Abraham MN, Yaipan OY, Brewer MR, et al. Angiotensin II enhances bacterial clearance via myeloid signaling in a murine sepsis model. Proc Natl Acad Sci USA. 2022;119:e2211370119. https:\/\/doi.org\/10.1073\/pnas.2211370119. Cited 2024 Jan 24.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3797_CR28","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.1053\/j.jvca.2019.03.004","volume":"33","author":"PM Wieruszewski","year":"2019","unstructured":"Wieruszewski PM, Radosevich MA, Kashani KB, Daly RC, Wittwer ED. Synthetic Human Angiotensin II for Postcardiopulmonary Bypass Vasoplegic Shock. J Cardiothorac Vasc Anesth. 2019;33:3080\u20134. https:\/\/doi.org\/10.1053\/j.jvca.2019.03.004. Cited 2023 Oct 28.","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"3797_CR29","doi-asserted-by":"publisher","first-page":"4496","DOI":"10.1053\/j.jvca.2022.07.022","volume":"36","author":"GA Car\u00e0","year":"2022","unstructured":"Car\u00e0 GA, Pasin L, Alborino E, Zarbock A, Bellomo R, Landoni G. Angiotensin II - A Brief Review and Role in Severe SARS-COV-2 Sepsis. J Cardiothorac Vasc Anesth. 2022;36:4496\u2013500. https:\/\/doi.org\/10.1053\/j.jvca.2022.07.022. Cited 2024 Jan 24.","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"3797_CR30","doi-asserted-by":"publisher","unstructured":"Chow JH, Mazzeffi MA, Mccurdy MT. Angiotensin II for the Treatment of COVID-19-Related Vasodilatory Shock. Anesth Analg. 2020;102-5. https:\/\/doi.org\/10.1213\/ANE.0000000000004825.","DOI":"10.1213\/ANE.0000000000004825"},{"key":"3797_CR31","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1002\/jmv.27592","volume":"94","author":"A Serpa Neto","year":"2022","unstructured":"Serpa Neto A, Landoni G, Ostermann M, Lumlertgul N, Forni L, Alvarez\u2010Belon L, et al. Angiotensin II infusion in COVID\u201019: An international, multicenter, registry\u2010based study. J Med Virol. 2022;94:2079\u201388. https:\/\/doi.org\/10.1002\/jmv.27592. Cited 2024 Dec 30.","journal-title":"J Med Virol"},{"key":"3797_CR32","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1053\/j.jvca.2020.07.087","volume":"35","author":"NS Cutler","year":"2021","unstructured":"Cutler NS, Rasmussen BM, Bredeck JF, Lata AL, Khanna AK. Angiotensin II for Critically Ill Patients With Shock After Heart Transplant. J Cardiothorac Vasc Anesth. 2021;35:2756\u201362. https:\/\/doi.org\/10.1053\/j.jvca.2020.07.087. Cited 2023 Oct 30.","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"2","key":"3797_CR33","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1177\/10600280221099928","volume":"57","author":"S Bird","year":"2023","unstructured":"Bird S, Chand M, Tran TL, Ali S, Awad SS, Cornwell LD, et al. Evaluation of the Addition of Angiotensin II in Patients With Shock After Cardiac Surgery at a Veterans Affairs Medical Center. Ann Pharmacother. 2023;57(2):141\u20137. https:\/\/doi.org\/10.1177\/10600280221099928. Cited 2023 Oct 28.","journal-title":"Ann Pharmacother"},{"issue":"3","key":"3797_CR34","doi-asserted-by":"publisher","first-page":"359","DOI":"10.4103\/aca.aca_98_21","volume":"25","author":"S Konkol","year":"2022","unstructured":"Konkol S, Morrisette M, Hulse M, Enfield K, Mihalek A. Outcomes following the use of angiotensin II in patients with postoperative vasoplegic syndrome: A case series. Ann Card Anaesth. 2022;25(3):359. https:\/\/doi.org\/10.4103\/aca.aca_98_21. Cited 2023 Oct 28.","journal-title":"Ann Card Anaesth"},{"key":"3797_CR35","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1186\/s13054-014-0534-9","volume":"18","author":"LS Chawla","year":"2014","unstructured":"Chawla LS, Busse L, Brasha-Mitchell E, Davison D, Honiq J, Alotaibi Z, et al. Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study. Crit Care. 2014;18:534. https:\/\/doi.org\/10.1186\/s13054-014-0534-9. Cited 2023 June 3.","journal-title":"Crit Care"},{"issue":"1","key":"3797_CR36","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13054-023-04446-1","volume":"27","author":"PM Wieruszewski","year":"2023","unstructured":"Wieruszewski PM, Bellomo R, Busse LW, Ham KR, Zarbock A, Khanna AK, et al. Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial. Crit Care. 2023;27(1):175. https:\/\/doi.org\/10.1186\/s13054-023-04446-1. Cited 2023 June 1.","journal-title":"Crit Care"},{"key":"3797_CR37","doi-asserted-by":"publisher","unstructured":"Zangrillo A, Landoni G, Beretta L, Morselli F, Neto AS, Bellomo R, et al. Angiotensin II infusion in COVID-19-associated vasodilatory shock: a case series. Critical Care. BMC. 2020;24. https:\/\/doi.org\/10.1186\/s13054-020-02928-0. Cited 2024 Sept 3.","DOI":"10.1186\/s13054-020-02928-0"},{"key":"3797_CR38","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/anae.15802","volume":"77","author":"TG Coulson","year":"2022","unstructured":"Coulson TG, Miles LF, Serpa Neto A, Pilcher D, Weinberg L, Landoni G, et al. A double\u2010blind randomised feasibility trial of angiotensin\u20102 in cardiac surgery *. Anaesthesia. 2022;77:999\u20131009. https:\/\/doi.org\/10.1111\/anae.15802. Cited 2024 Sept 3.","journal-title":"Anaesthesia"},{"key":"3797_CR39","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1097\/SHK.0000000000002109","volume":"59","author":"EJ See","year":"2023","unstructured":"See EJ, Clapham C, Liu J, Khasin M, Liskaser G, Chan JW, et al. A pilot study of angiotensin II as primary vasopressor in critically ill adults with vasodilatory hypotension: The ARAMIS Study. Shock. 2023;59:691\u20136. https:\/\/doi.org\/10.1097\/SHK.0000000000002109. Cited 2023 Oct 28.","journal-title":"Shock"},{"key":"3797_CR40","doi-asserted-by":"publisher","first-page":"e0230","DOI":"10.1097\/CCE.0000000000000230","volume":"2","author":"DE Leisman","year":"2020","unstructured":"Leisman DE, Mastroianni F, Fisler G, Shah S, Hasan Z, Narasimhan M, et al. Physiologic response to angiotensin II treatment for Coronavirus Disease 2019\u2013induced vasodilatory shock: a retrospective matched cohort study. Crit Care Explor. 2020;2:e0230. https:\/\/doi.org\/10.1097\/CCE.0000000000000230. Cited 2024 Sept 21.","journal-title":"Crit Care Explor"},{"key":"3797_CR41","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1016\/j.athoracsur.2018.11.047","volume":"108","author":"A Evans","year":"2019","unstructured":"Evans A, McCurdy MT, Weiner M, Zaku B, Chow JH. Use of angiotensin II for post cardiopulmonary Bypass vasoplegic syndrome. Ann Thorac Surg. 2019;108:e5-7. https:\/\/doi.org\/10.1016\/j.athoracsur.2018.11.047. Cited 2023 Oct 28.","journal-title":"Ann Thorac Surg"},{"key":"3797_CR42","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1053\/j.jvca.2020.08.001","volume":"35","author":"A Klijian","year":"2021","unstructured":"Klijian A, Khanna AK, Reddy VS, Friedman B, Ortoleva J, Evans AS, et al. Treatment with angiotensin II is associated with rapid blood pressure response and vasopressor sparing in patients with vasoplegia after cardiac surgery: a post-hoc analysis of angiotensin ii for the treatment of high-output shock (ATHOS-3) study. J Cardiothorac Vasc Anesth. 2021;35:51\u20138. https:\/\/doi.org\/10.1053\/j.jvca.2020.08.001. Cited 2023 Oct 28.","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"3797_CR43","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/S1388-9842(01)00155-6","volume":"3","author":"SR Bennett","year":"2001","unstructured":"Bennett SR, McKeown J, Drew P, Griffin S. Angiotensin in cardiac surgery: efficacy in patients on angiotensin converting enzyme inhibitors. Eur J Heart Fail. 2001;3:587\u201392. https:\/\/doi.org\/10.1016\/S1388-9842(01)00155-6. Cited 2024 Sept 26.","journal-title":"Eur J Heart Fail"},{"key":"3797_CR44","doi-asserted-by":"publisher","first-page":"e01266","DOI":"10.1213\/XAA.0000000000001266","volume":"14","author":"NS Cutler","year":"2020","unstructured":"Cutler NS, Khanna AK. Catecholamine-sparing effect of angiotensin II in an anephric patient with mixed shock after cardiac revascularization surgery: a case report. A&A Practice. 2020;14:e01266. https:\/\/doi.org\/10.1213\/XAA.0000000000001266. Cited 2023 Oct 28.","journal-title":"A&A Practice"}],"container-title":["BMC Anesthesiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12871-026-03797-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12871-026-03797-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12871-026-03797-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:30:43Z","timestamp":1781645443000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12871-026-03797-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3797"],"URL":"https:\/\/doi.org\/10.1186\/s12871-026-03797-w","relation":{},"ISSN":["1471-2253"],"issn-type":[{"value":"1471-2253","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,6]]},"assertion":[{"value":"31 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not a source of conflict as data is extrapolated from current available systematic reviews. Human ethics and consent to participate declarations not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"257"}}